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with typical antipsychotics and risperidone orally disintegrating
tablets and highest with depot risperidone formulation. This
ﬁnding is consistent with the results reported in the CATIE study
where only 25–45% of patients continued on oral treatment after
one year. Retention on medication is an important aspect of
patient outcomes in schizophrenia; these data suggest that reten-
tion on depot risperidone may be improved compared to other
treatments.
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OBJECTIVE: To identify treatment patterns and illness charac-
teristics preceding the initiation of depot typical antipsychotics in
the treatment of schizophrenia patients who are non-adherent
with oral antipsychotic regimens. METHODS: Data were drawn
from a large, multi-site, 3-year prospective non-interventional
observational study of schizophrenia patients in the U.S, con-
ducted between July 1997 and September 2003. The analytical
sample included patients who—in the six months prior to
enrollment—were non-adherent with oral antipsychotics and
were not treated with depot antipsychotics (N = 314). Non-
adherent patients who were subsequently initiated on typical
depots during the 3-year follow-up were compared with patients
continuing therapy with only oral agents. Comparisons were
made on clinical, functional, and treatment variables assessed at
predetermined intervals with standard psychiatric measures, a
patient self-report questionnaire, and medical record informa-
tion. RESULTS: A small proportion of patients (12.4%) previ-
ously non-adherent with oral antipsychotics were subsequently
initiated on a depot therapy during the 3-year study. Compared
to patients treated with only oral antipsychotics, those subse-
quently initiated on a depot were signiﬁcantly more likely to be
hospitalized at depot initiation or during the previous six
months, were more likely to have recent legal involvement, illicit
drug use, and treatment with more antipsychotics during the 3
months prior to initiation. CONCLUSION: Despite prior non-
adherence with antipsychotic medication, only a small propor-
tion of non-adherent schizophrenia patients were initiated on
depot antipsychotics in this 3-year prospective study. Patients
who were subsequently initiated on depot had a distinct treat-
ment pattern and illness proﬁle preceding initiation of the depot
medication.
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OBJECTIVES: To assess the reporting and scientiﬁc quality of
meta-analyses (MAs) of randomized controlled trials (RCTs) as
treatments for anxiety disorders. METHODS: We searched
EMBASE, EBM Reviews, MEDLINE, Healthstar and IPA from
inception to August 2007. Search terms included: MA, RCTs,
anxiety, anxiolytic, anti-depressant/antidepressant and cognitive
therapy with no language restrictions. Titles and abstracts were
assessed by two reviewers independently. Criteria for full-text
retrieval included: MA, statistical pooling, anxiety disorder,
RCT, pharmacotherapy, cognitive therapy. RCTs examining
anxiety symptoms were excluded. A manual search of refer-
ences was performed. Quality was assessed independently by
two raters, using the Quality of Reporting of Meta-analyses
checklist (QUOROM) and the Overview Quality Assessment
Questionnaire (OQAQ). Kendall’s tau measured inter-rater reli-
ability with statistical signiﬁcance at P  0.05. Means and stan-
dard deviations described the overall quality. A time series
analysis was performed. RESULTS: In total, 136 titles and
abstracts were reviewed; 48 were retrieved, including six from
the manual search. Twelve were excluded (not pooled analyses,
inappropriate condition or treatment or were duplicates),
leaving 36 studies. Publication dates ranged from 1990–2007.
Agreement was high; tau = 0.856 (P < 0.05) for QUOROM and
0.865 (P < 0.05) for OQAQ. The mean overall QUOROM
score was 65% (SD = 18%). The ‘results’ category yielded the
lowest quality scores while the introductions and discussions
yielded the highest. The mean overall OQAQ score was 59%
(SD = 25%). Flaws in scientiﬁc quality were observed regard-
ing ‘avoidance of bias’ and ‘validity’ while most studies linked
the results to the primary objective appropriately. There was
a small, non-signiﬁcant increase in quality of MAs over the
years observed. CONCLUSIONS: Reporting and scientiﬁc
quality of MAs in anxiety were only fair. They were, however,
higher than those previously reported for depression and criti-
cal care.
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OBJECTIVE: To evaluate clinical and functioning outcomes of
risperidone long-acting injection (RLAI) treatment in patients
with schizophrenia enrolled in the electronic-Schizophrenia
Treatment Adherence Registry (e-STAR) from Czech Republic
and Slovakia. METHODS: e-STAR is an international, long-
term, prospective, observational study of patients with schizo-
phrenia who commence RLAI treatment. Data are collected
retrospectively for one year and prospectively every three months
for two years. Clinical outcomes were measured by Clinical
Global Impression-Severity (CGI-S) scale and patient functioning
was assessed using Global Assessment of Functioning (GAF)
scale. This interim report is based on data from patients who
have completed their 18-month follow-up visit. RESULTS: To
date, a total of 1324 patients have been enrolled in e-STAR from
the Czech Republic and Slovakia; 296 patients with at least
18-months of data available (97.3% still on RLAI) were included
in this analysis. Of the 296 patients, 53.7% were male with a
mean age of 37.6  12.0 years and a mean time since diagnosis
of 9.6  9.0 years. Mean CGI-S score signiﬁcantly decreased
from 4.6 plusmn; 1.1 at baseline to 2.9  1.0 at 18 months
(p < 0.001). Proportion of patients with not ill/very mild/mild
illness increased from 13.5% to 75.6% and that of patients with
marked/severe/extremely severe decreased from 48.8% to
6.3% (p < 0.001) compared to baseline. Meanwhile, patient
global functioning has signiﬁcantly improved as the mean GAF
score increased signiﬁcantly from 49.9  15.2 at baseline to
73.8  14.5 at 18 months (p < 0.001). CONCLUSION: Signiﬁ-
cant improvements in disease severity and functioning from base-
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